Biomarin Pharmaceutical Inc (BMRN) financials · rev $3.22B
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Biomarin Pharmaceutical Inc (BMRN) rev $3.22B.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.22B | $2.85B |
| Cost of Revenue | $717.4M | $580.2M |
| Gross Profit | $2.50B | $2.27B |
| Operating Income | $409.5M | $484.2M |
| Net Income | $348.9M | $426.9M |
| EPS (Diluted) | $1.80 | $2.21 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $7.59B | $6.99B |
| Current Assets | $3.95B | $3.23B |
| Cash & Equivalents | $1.31B | $942.8M |
| Inventory | $1.30B | $1.23B |
| PP&E | $952.5M | $1.04B |
| Total Liabilities | $1.51B | $1.33B |
| Current Liabilities | $759.0M | $607.0M |
| Short-term Debt | N/A | N/A |
| Long-term Debt | $597.2M | N/A |
| Total Debt | $597.2M† | N/A |
| Shareholders' Equity | $6.09B | $5.66B |
| Retained Earnings | $154.2M | -$194.7M |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $828.0M | $572.8M |
| CapEx | $103.0M | $85.4M |
| Investing Cash Flow | -$414.2M | $136.5M |
| Financing Cash Flow | -$42.4M | -$526.4M |
| Net Change in Cash | $368.8M | $187.7M |
| Free Cash Flow | $725.0M | $487.4M |
FAQ
What is BMRN P/E and revenue?
Biomarin Pharmaceutical Inc (BMRN) rev $3.22B.
What is BMRN revenue?
Biomarin Pharmaceutical Inc last cached revenue is $3.22B (FY2025).
Is BMRN profitable?
Biomarin Pharmaceutical Inc last cached net income is $348.9M (FY2025).
What are BMRN total assets?
Biomarin Pharmaceutical Inc last cached total assets are $7.59B (FY2025).
What is BMRN free cash flow?
Biomarin Pharmaceutical Inc last cached free cash flow is $725.0M (FY2025).
Not investment advice. Cached statements, not a live tape.